CN111450101B - Application of imidazole pyridine derivative in preparation of medicines - Google Patents
Application of imidazole pyridine derivative in preparation of medicines Download PDFInfo
- Publication number
- CN111450101B CN111450101B CN202010059361.9A CN202010059361A CN111450101B CN 111450101 B CN111450101 B CN 111450101B CN 202010059361 A CN202010059361 A CN 202010059361A CN 111450101 B CN111450101 B CN 111450101B
- Authority
- CN
- China
- Prior art keywords
- mice
- compound
- preparation
- medicament
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 15
- SBPIDKODQVLBGV-UHFFFAOYSA-N 1h-imidazole;pyridine Chemical class C1=CNC=N1.C1=CC=NC=C1 SBPIDKODQVLBGV-UHFFFAOYSA-N 0.000 title claims abstract description 4
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 229940079593 drug Drugs 0.000 title description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 238000011282 treatment Methods 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 2
- 206010055171 Hypertensive nephropathy Diseases 0.000 claims description 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 1
- 125000004857 imidazopyridinyl group Chemical class N1C(=NC2=C1C=CC=N2)* 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 21
- 208000020832 chronic kidney disease Diseases 0.000 abstract description 9
- 201000001421 hyperglycemia Diseases 0.000 abstract description 8
- 206010020772 Hypertension Diseases 0.000 abstract description 6
- 208000017169 kidney disease Diseases 0.000 abstract description 4
- 206010061481 Renal injury Diseases 0.000 abstract description 2
- 239000000411 inducer Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 18
- 206010016654 Fibrosis Diseases 0.000 description 12
- 230000004761 fibrosis Effects 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 210000005084 renal tissue Anatomy 0.000 description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000001434 glomerular Effects 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000010339 dilation Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 102220470475 L-seryl-tRNA(Sec) kinase_C57L_mutation Human genes 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000013118 diabetic mouse model Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000000585 glomerular basement membrane Anatomy 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000004926 tubular epithelial cell Anatomy 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010023421 Kidney fibrosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000008721 basement membrane thickening Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 108010015046 cell aggregation factors Proteins 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 206010038464 renal hypertension Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910000275 saponite Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of an imidazole pyridine derivative or a salt thereof in preparation of a medicament, wherein the compound is used for treating or preventing chronic kidney diseases, preferably kidney diseases caused by hyperglycemia or hypertension, but is not limited to the two inducers, and particularly, the medicament can inhibit or improve various kidney injuries.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to application of a compound (code number X22) of a formula (I) or pharmaceutically acceptable salt thereof in preparation of a medicine for treating or preventing chronic kidney disease.
Background
Chronic kidney disease is one of the most common complications of basal diseases such as hyperglycemia or hypertension. Upon stimulation by these risk factors, glomerular basement membrane thickens and tubular interstitium expands to progressive fibrosis. As the disease progresses, it eventually progresses to end-stage renal disease, severely affecting the quality of life of the patient and even endangering life.
Based on pharmacological and pathological mechanism researches for many years, the inventor discovers that the compound with the X22 structure can effectively treat chronic kidney disease induced by multifactorial factors such as hyperglycemia, hypertension and the like, and the pathology related to the kidney disease can be obviously improved.
Disclosure of Invention
The invention aims at providing a novel application of 4- {5' - [3' -propyl-2 ' - [3' - (1 ' -methyl) indolyl ] -imidazo [4,5-b ] pyridine ] yl } morpholin (a compound of formula (I), with a code X22).
In particular, the invention provides the use of a compound (X22) of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis of chronic kidney disease.
Preferably the use of the invention is in the manufacture of a medicament for the treatment or prophylaxis of chronic kidney disease.
The invention also provides the use of a compound (X22) of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for ameliorating chronic kidney disease.
Preferably the use of the invention is in the manufacture of a medicament for ameliorating chronic kidney disease.
Kidney disease occurs in a variety of etiologies including urinary system obstruction, hyperlipidemia, hypertension, autoimmunity, drug toxicity reactions, and the like. The treatment modes of the different etiologies are different, and the invention is mainly aimed at diabetic nephropathy or hypertensive nephropathy, but is not limited to the two causative factors; most preferably, for the treatment of kidney injury and altered renal tissue function.
Preferably, in the use of the present invention, the main pathological feature of kidney disease is glomerulosclerosis and tubular dilation.
The renal tissue function alterations include proteinuria, reduced renal function, tubular fibrosis, and thickening of the basement membrane.
Preferably, in the use of the present invention, the effect of the compound (X22) of formula (I) or a salt thereof on blood glucose or blood pressure is not statistically significant.
The medicament for use in the present invention contains an effective dose of the compound (X22) of formula (I). The effective dose may be the amount of drug in a unit dosage form (e.g., a tablet, a needle, a pill, or a dose), or may be a unit dose (e.g., a unit body weight dose) of a patient in need of treatment/prophylaxis. In the present invention, an effective dose (in terms of content) may be 10. Mu.g to 1g, preferably 0.1mg to 500mg, more preferably 1mg to 100mg.
The medicament for use in the present invention will generally also contain a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier used refers to nontoxic fillers, stabilizers, diluents, adjuvants or other formulation adjuvants. For example, diluents, excipients, such as water, physiological saline, and the like; fillers such as starch, sucrose, etc.; binders, such as cellulose derivatives, alginates, gelatin and/or polyvinylpyrrolidone; humectants, such as glycerol; disintegrants, such as agar-agar, calcium carbonate and/or sodium bicarbonate; absorption promoters, such as quaternary ammonium compounds; surfactants such as cetyl alcohol; adsorption carriers such as kaolin and/or saponite clay; lubricants such as talc, calcium/magnesium stearate, polyethylene glycol, and the like. In addition, the pharmaceutical composition of the present invention may further contain other auxiliary materials such as flavoring agents, sweeteners, etc. The pharmaceutical composition may be formulated into various dosage forms according to the purpose of treatment and the need of the administration route, preferably the composition is in the form of unit administration dosage such as lyophilized preparation, tablet, capsule, powder, emulsion, water injection or spray, more preferably the pharmaceutical composition is in the form of injection (e.g., lyophilized powder injection) or oral dosage form (e.g., tablet, capsule). The medicament may be administered by conventional routes, in particular enterally, e.g. orally, e.g. in the form of tablets or capsules, or parenterally, e.g. in the form of injectable solutions or suspensions, topically, e.g. in the form of lotions or gels, or in the form of nasal or test agents.
The present invention will be described in detail below with reference to specific examples and drawings. It should be particularly pointed out that these descriptions are only a few exemplary descriptions and are not intended to limit the scope of the invention. Many variations and modifications of the invention will be apparent to those skilled in the art in light of the teachings of this specification.
Description of the drawings:
FIG. 1 shows the effect of compound (X22) of formula (I) on blood glucose and body weight of diabetic rats and the improvement of model urine proteins and kidney function.
FIG. 2 shows the inhibitory effect of compound (X22) of formula (I) on kidney fibrosis in diabetic mice.
FIG. 3 shows the inhibitory effect of the compound (X22) of formula (I) on in vitro tubular epithelial cell fibrosis caused by high concentration glucose.
FIG. 4 shows the therapeutic effect of compound (X22) of formula (I) on AngII-induced hypertensive glomerular fibrosis and enlargement.
The specific embodiment is as follows:
the invention is further illustrated in the following examples. These examples are for the purpose of illustrating the invention only and are not intended to limit the scope of the invention.
Example 1 the compounds of the invention do not affect blood glucose and body weight in mice.
The C57L/B6 mice were randomly divided into 3 groups (6 per group) of:
control group (Control group): healthy C57L/B6 mice;
model type 1 diabetes mice (STZ): constructing a model of type 1 diabetes mice using Streptozotocin (STZ);
compound treatment group (stz+x22 10 mg/kg): after completion of the construction of type 1 diabetic model mice, the mice were given the compound of formula (I) (X22), 1% CMC-Na suspension, starting at the 9 th week at a dose of 10mg/kg/day, by intragastric administration for 8 consecutive weeks.
Blood glucose (Blood glucose) and body weight (weight) were recorded weekly for each group during 16 weeks after molding. The results are shown in fig. 1A, with no difference in blood glucose levels between the treated mice and STZ mice. Meanwhile, the application of compound (X22) did not affect the body weight of the diabetic mouse model.
Mice were sacrificed after the end of the dosing period, kidney weights of the mice were individually weighed, compared to body weight and plotted. The results show that the increase in renal tissue weight ratio due to hyperglycemia can be significantly reduced by X22, see fig. 1B. Meanwhile, urine samples are collected, and urine proteins and urine creatinine are detected by biochemical analysis. Figures 1C-D show that compound (X22) of formula (I) significantly alleviates high sugar-induced urinary protein and renal dysfunction.
EXAMPLE 2 the compounds of the invention significantly inhibit hyperglycemia-induced renal fibrosis
Animals were grouped as in example 1, mice were sacrificed and kidney tissue was obtained 8 weeks after dosing. 4% formalin fixation, paraffin embedding, 5 μm thickness sections were followed by hematoxylin & eosin (H & E) staining, sirius Red (Sirus Red) staining and microscopy. Fig. 2A shows that hyperglycemia causes glomerular hypertrophy, glomerular basement membrane thickening, tubular dilation; at the same time, tubular interstitial fibrosis is caused, but the pathological features are significantly relieved after X22 treatment.
In addition, collagen 4 (COL-4) and a fibrosis marker TGF-beta were detected by Western immunoblotting. FIG. 2B shows that COL-4 and TGF-beta were significantly increased in the STZ group, while X22 significantly inhibited the expression of these proteins (p < 0.05).
After the tissues are crushed and RNA is extracted, the real-time quantitative PCR method is utilized to respectively detect fibrosis related markers COL-4 and TGF-beta; cell adhesion factors VCAM and ICAM. As shown in FIGS. 2C-D, X22 significantly inhibited COL-4, TGF-. Beta., VCAM, ICAM expression in the kidney caused by hyperglycemia.
Example 3 the compounds of the invention significantly improve fibrosis of tubular epithelial cells in vitro caused by hyperglycemia.
NRK-52E cells were stimulated with high concentration of glucose (HG, 33 mM) for 24 hours, followed by lysis of the cells to obtain total protein and detection of fibrosis-associated proteins COL-4, TGF-beta using Western blotting, with GAPDH as an internal reference. As shown in FIG. 3A, the increase in COL-4 and TGF-beta expression induced by HG can be significantly inhibited by X22. In addition, NRK-52E cells were stimulated with HG for 10 hours, total RNA from the cells was extracted with TRIzol, and the RNA expression levels of COL-4, TGF-. Beta., VCAM, ICAM were detected by using a real-time quantitative PCR method. The results are shown in FIGS. 3B-E, X22 also significantly inhibited HG-induced fibrosis and increased levels of cell adhesion factor RNA in vitro.
EXAMPLE 4 Compounds of the invention do not affect mouse blood pressure but significantly improve hypertension-induced glomerular fibrosis, enlargement
The C57BL/6 mice are divided into 3 groups, and 6 mice in each group are respectively:
blank control (Ctrl): healthy mice;
renal hypertension model group (AngII): subcutaneous micropump injection (1000 ng/kg/min) using AngII was performed for 4 weeks;
treatment group (Ang II+X22 10 mg/kg): subcutaneous micropump injection (1000 ng/kg/min) using Ang II for 2 weeks; mice were given a gastric administration of the compound of formula (I) at a dose of 10mg/kg/day on day 15 for 2 consecutive weeks.
As shown in fig. 4A and 4B, the blood pressure of the mice in the treatment group was not significantly different from that of AngII, indicating that the formula (I) did not affect the blood pressure of the mice in the model, and the pharmacological effect was not achieved by lowering blood pressure. After administration, mice are sacrificed, kidney tissues are taken, 4% formalin is used for fixation, paraffin embedding is carried out, hematoxylin & eosin (H & E) staining is carried out after 5 mu m thickness of sections are cut, sirius Red (Sirus Red) staining is carried out, and microscopic examination is carried out; simultaneously, the level of TNF-alpha is detected by an immunohistochemical method. FIG. 4B shows that AngII causes glomerular hypertrophy and tubular dilation; at the same time, tubular interstitial fibrosis is caused, and the pathological characteristics of the X22 after treatment are obviously improved.
Claims (1)
1. The use of an imidazopyridine derivative or a salt thereof in the manufacture of a medicament for the treatment of diabetic nephropathy or hypertensive nephropathy;
the imidazole pyridine derivative is 4- {5' - [3' -propyl-2 ' - [3' ' - (1 ' ' -methyl) indolyl ] -imidazole [4,5-b ] pyridine ] yl } morpholine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010059361.9A CN111450101B (en) | 2020-01-18 | 2020-01-18 | Application of imidazole pyridine derivative in preparation of medicines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010059361.9A CN111450101B (en) | 2020-01-18 | 2020-01-18 | Application of imidazole pyridine derivative in preparation of medicines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111450101A CN111450101A (en) | 2020-07-28 |
| CN111450101B true CN111450101B (en) | 2023-12-05 |
Family
ID=71671843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010059361.9A Active CN111450101B (en) | 2020-01-18 | 2020-01-18 | Application of imidazole pyridine derivative in preparation of medicines |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111450101B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117257810B (en) * | 2023-09-22 | 2024-06-18 | 湖南普瑞玛药物研究中心有限公司 | Application of imidazopyridine derivative in preparation of medicines for treating or preventing myeloproliferative neoplasms |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103145706A (en) * | 2012-11-16 | 2013-06-12 | 温州医学院 | Imidazopyridine compound with anti-inflammatory action and application thereof to preparation of anti-inflammatory medicament |
-
2020
- 2020-01-18 CN CN202010059361.9A patent/CN111450101B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103145706A (en) * | 2012-11-16 | 2013-06-12 | 温州医学院 | Imidazopyridine compound with anti-inflammatory action and application thereof to preparation of anti-inflammatory medicament |
Non-Patent Citations (3)
| Title |
|---|
| Inhibition of ROS and inflammation by an imidazopyridine derivative X22 attenuate high fat diet-induced arterial injuries;Li W等;《Vascular Pharmacology》;第72卷;第153-162页 * |
| Synthesis and anti-inflammatory evaluation of novel benzimidazole and imidazopyridine derivatives;Chen G等;《ACS Medicinal Chemistry Letters》;第04卷(第01期);第69-74页 * |
| The imidazopyridine derivative X22 prevents diabetic kidney dysfunction through inactivating NF-κB signaling;Jiang Y等;《Biochemical and Biophysical Research Communications》;第525卷(第04期);第877-882页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111450101A (en) | 2020-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bakris et al. | Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications | |
| KR100552043B1 (en) | Composition for obesity treatment comprising fumagillol derivatives | |
| US10463654B2 (en) | Combination therapies for treating cancer | |
| JP2010509283A (en) | Combination therapy with SGLT-2 inhibitors and pharmaceutical compositions thereof | |
| AU2018202986B2 (en) | ANG-(1-7) derivative oligopeptides and methods for using and producing the same | |
| CN111358789B (en) | Application of NSC228155 in preparation of medicine for preventing and treating chronic renal fibrosis | |
| CN111450101B (en) | Application of imidazole pyridine derivative in preparation of medicines | |
| CN110664790A (en) | Application of 2, 6-di (2- (trifluoromethyl) benzylidene) cyclohexanone in medicine preparation | |
| EP2289520A1 (en) | Use of acetylsalicylic acid for the prophylaxis and/or treatment of influenza virus infection. | |
| KR20050106038A (en) | Adenosine a1 receptor antagonist for the treatment of cardiac and renal diseases | |
| US9428466B2 (en) | Methods for reducing uric acid levels using barbiturate derivatives | |
| CN116196323B (en) | Application of typha saponin in preparing medicament for reducing uric acid and/or treating kidney injury | |
| KR102401604B1 (en) | New uses for desmethylclozapine | |
| CN111450095A (en) | Application of N- (thiazole-2-yl) -3- (piperazine-1-yl) propionamide compound in medicine preparation | |
| CN112535682B (en) | Application of Shaerweike ketone derivative in preparation of medicine | |
| US20200129473A1 (en) | Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer | |
| CN113440519A (en) | Application of mycophenolic acid and derivatives thereof in preparation of drugs for targeted therapy of cancers | |
| CN110038009B (en) | Application of canagliflozin in preparation of antitumor drugs | |
| AU2020341562A1 (en) | Inhibitors of SGLT and uses thereof | |
| CN109700807B (en) | Application of compound RH-1402 in preparation of acute kidney injury resistant medicine | |
| CN116492342B (en) | Application of chloroquine or hydroxychloroquine in preparation of medicine for treating nilotinib kidney toxic and side effects | |
| CN117731654B (en) | New application of JJH201601 in treatment of primary glioma and recurrent glioma | |
| US20240197692A1 (en) | Combination Comprising Everolimus and Amcenestrant | |
| CN109010335A (en) | Purposes of the 2,4- thiazolidine dione compounds K145 in preparation treatment diabetes medicament | |
| CN112386600B (en) | Application of Hupeimine in preparation of medicine for preventing acute kidney injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |